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Abstract: Cone snails are predatory creatures using venom as a weapon for prey capture and
defense. Since this venom is neurotoxic, the venom gland is considered as an enormous collection of
pharmacologically interesting compounds having a broad spectrum of targets. As such, cone snail
peptides represent an interesting treasure for drug development. Here, we report five novel peptides
isolated from the venom of Conus longurionis, Conus asiaticus and Conus australis. Lo6/7a and
Lo6/7b were retrieved from C. longurionis and have a cysteine framework VI/VII. Lo6/7b has
an exceptional amino acid sequence because no similar conopeptide has been described to date
(similarity percentage <50%). A third peptide, Asi3a from C. asiaticus, has a typical framework III Cys
arrangement, classifying the peptide in the M-superfamily. Asi14a, another peptide of C. asiaticus,
belongs to framework XIV peptides and has a unique amino acid sequence. Finally, AusB is a novel
conopeptide from C. australis. The peptide has only one disulfide bond, but is structurally very
different as compared to other disulfide-poor peptides. The peptides were screened on nAChRs,
NaV and KV channels depending on their cysteine framework and proposed classification. No targets
could be attributed to the peptides, pointing to novel functionalities. Moreover, in the quest of
identifying novel pharmacological targets, the peptides were tested for antagonistic activity against a
broad panel of Gram-negative and Gram-positive bacteria, as well as two yeast strains.
Keywords: Conus; conotoxin; electrophysiology; antimicrobial tests; peptide characterization
1. Introduction
The existence of venomous animals represents a unique starting point for bio-discovery and drug
design. Over millions of years, nature has optimized the constituents of venoms (i.e., peptide toxins)
as the most selective and potent tools on Earth [1,2]. Therefore, such toxins can be used as lead
compounds for a novel generation of drugs. The venom peptides from cone snails (genus Conus) are
generally small cysteine-rich peptides with the unique feature of being highly selective and potent
ligands for a wide range of ion channels and receptors [3]. Consequently, they are recognized as lead
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compounds in the quest for novel therapeutics in diseases, such as multiple sclerosis, epilepsy, long QT
syndrome and many other neurological disorders [4,5].
Conopeptides are classified in two main groups based on the presence and number of cysteine
bonds, namely disulfide-rich and disulfide-poor conopeptides. The peptides from the first category
are called conotoxins and have multiple disulfide bonds. Peptides from the second category contain
none or only one disulfide bond. Disulfide-poor conopeptides are subdivided into contulakines
(interacting with neurotensin receptors), conantokines (interacting with N-methyl-D-aspartate
receptor), conorfamids (interacting with RFamide receptor), conolysines (interacting with cellular
membranes), conopressins (interacting with vasopressin receptors), contryphans (interacting with
CaV or KV channels), conophans (target unknown), conomarphines (target unknown) and conomaps
(target unknown) [6,7]. The disulfide-rich conotoxins are classified into superfamilies based on a
conserved signal sequence and their characteristic cysteine network. Conotoxins with a similar
cysteine network carry a similar signal sequence. Further subdivision in families is made based
on the receptor with which they interact [6]. These receptors are mainly voltage- and ligand-gated ion
channels. Some components act on G-protein coupled receptors and neurotransmitter transporters,
whereas others show enzymatic activity [2,7]. To date, at least 16 superfamilies have been
discovered [6,7].
Voltage-gated sodium channels (VGSCs or NaVs) are transmembrane proteins that are activated
by depolarization of the cell membrane. In excitable cells, they play a central role in the generation
and propagation of action potentials, in close collaboration with other channels like voltage-gated
potassium channels [8]. Nine mammalian channel isoforms of the NaV1.X subfamily have been
functionally characterized, and several insect channels have been successfully cloned and expressed [9].
The mammalian NaV isoforms have similar structural and functional properties, but are present in
different cell types (neurons, neuro-endocrine cells, skeletal muscle cells, heart cells); and they possess
diverse functional properties in the corresponding tissues [10]. Furthermore, defective NaVs cause
several diseases or channelopathies, such as epileptic disorders, neuromuscular diseases, cancer and
cardiomyopathies. Blocking the aberrant Na+ current can be an effective strategy in treating these
disorders [11].
The molecular diversity of K+ channels is larger than any other group of ion channels, with more
than 80 different genes and many splice variants [12]. Voltage-gated potassium channels (VGPC or KVs)
are responsible for the repolarization of membranes following a neuron-initiated action potential.
KV channels are specifically and widely distributed and are located in the brain, nervous system, heart,
skeletal muscle, hematopoietic cells, lymphocytes and osteoclasts [13]. They are involved in many
physiological processes, such as regulation of heart rate, neuronal excitability, muscle contraction,
neurotransmitter release, insulin secretion, Ca2+ signaling, cellular proliferation and migration and
cell volume regulation [14].
Nicotinic acetylcholine receptors (nAChRs) are a member of the ligand-gated cationic channel
family and mediate fast synaptic transmission. They are broadly distributed throughout the peripheral
and central nervous systems of both simple and evolutionarily complex organisms [15]. In mammals,
there are 16 different nAChR subunits: nine different α-subunits (α1–7, α9 and α10), four β-subunits
(β1–4), as well as γ, δ and ε subunits. Five of these subunits combine to form muscle nAChR subtypes
(α1β1γδ and α1β1δε), which are found at neuromuscular junctions, whereas the rest (α2–α10, β2–β4)
assembles in numerous homomeric (α-subunits exclusively) or heteromeric (α- and β-subunits)
neuronal nAChR subtypes [16]. The assembly of different pentamers forms a complex variety of
nAChR subtypes with different pharmacological and biophysical properties [17].
This study describes the isolation and purification of novel conopeptides from Conus longurionis,
Conus asiaticus and Conus australis that were collected from the Tamil Nadu coast, in the Indian
Ocean. To the best of our knowledge, this is the first report of a conopeptide from the venom
of C. asiaticus, while other conotoxins from C. longurionis and C. australis have been described
earlier [18,19]. Toxins were electrophysiologically screened against a panel of NaVs, KVs, as well as
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nAChRs. Moreover, in the quest of identifying novel pharmacological targets of conopeptides,
we tested these peptides for potential antimicrobial activity.
2. Results
2.1. Isolation of Novel Conotoxins from C. longurionis, C. asiaticus and C. australis
Venom glands of three largely unexplored cone snail species, C. longurionis, C. asiaticus and
C. australis, were investigated. Samples were purified via a series of HPLC purification steps.
Amino acid sequences of the purified compounds were determined via N-terminal Edman degradation,
revealing five new conotoxin sequences (Table 1).
Table 1. Overview of the peptides discussed in this work.
Name Amino Acid Sequence CysteineArrangement
Cysteine
Framework Source
Lo6/7a DQCSYCGIYCCPPKFCTSAGCRSP * C–C–CC–C–C VI/VII C. longurionis
Lo6/7b SCLSSGALCGIDSNCCNGCNVPRNQCY * C–C–CC–C–C VI/VII C. longurionis
Asi3a CCQWPCSHGCIPCCY * CC–C–C–CC III C. asiaticus
Asi14a SCGYPCSHCGIPGCYPG * C–C–C–C XIV C. asiaticus
AusB GAYFDGFDVPCVPRRDDC C–C N.A. C. australis
* Indicates C-terminal amidation. N.A.: not available.
The first peptide, Lo6/7a is a novel 24-residue conotoxin with a molecular mass of 2583.0 Da
(folded). This is in perfect agreement with the mass of the unfolded synthetic peptide (2589.0 Da),
determined by LC-MS and the theoretically calculated masses for oxidized (2583.0 Da) and reduced
(2589.0 Da) Lo6/7a. According to its cysteine pattern, C–C–CC–C–C, Lo6/7a belongs to framework
VI/VII, covered by different superfamilies: I, O and M.
The second peptide, Lo6/7b, has a molecular mass of 2775.1 Da (folded peptide) determined by
MALDI-TOF. This mass resembles the mass of the unfolded synthetic peptide (2781.1 Da), determined
by LC-MS and the theoretically calculated masses of oxidized (2775.1 Da) and reduced (2781.1 Da)
Lo6/7b. The cysteine pattern of Lo6/7b is the same as for Lo6/7a, C–C–CC–C–C and therefore also
belongs to superfamilies I, O and M and framework VI/VII. The RP-HPLC purification chromatogram
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Figure 1. C18 RP-HPLC purification of C. longurionis, showing peptides Lo6/7a and Lo6/b. The brown
line shows the acetonitrile gradient.
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Asi3a and Asi14a were retrieved from C. asiaticus, a worm hunting cone snail species found in the
Indian Ocean at the coast of Tamil Nadu (India) and represent the first conopeptides isolated from
this species. The molecular mass of Asi3a is 1697.6 Da (folded) obtained by MALDI-TOF which is
in perfect agreement with the mass of the synthetic unfolded peptide 1703.0 Da and the theoretical
masses of folded Asi3a (1696.1 Da) and unfolded (1702.1 Da) peptide. Asi3a has cysteine framework
CC–C–C–CC, characteristic for framework III, found in the M-superfamily.
Asi14a has a molecular mass of 1697.6 Da (folded), determined by MALDI-TOF. The mass of the
unfolded synthetic peptide is 1700.0 Da. The calculated mass of oxidized Asi14a is 1695.9 Da, and the
reduced calculated mass is 1699.9 Da. Asi14a has a framework XIV cysteine arrangement (C–C–C–C),
as found in the A, L and J superfamilies. The purification of the crude venom of C. asiaticus is shown in
Figure 2. The RP-HPLC chromatogram of the first purification step is shown in Figure 2A. In Figure 2B,
the ion exchange chromatogram is shown, whereas a third purification via RP-HPLC revealed the
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(D) RP‐HPLC2  chromatogram, as  indicated  in Figure 2B. Edman degradation of  this peak, Asi3a, 
revealed  the amino acid sequence as described above. The brown  lines  in  (A,C,D) are acetonitrile 
gradients. The line in (B) shows the ion exchange gradient. 
The last peptide was found in the venom of C. australis and was named AusB. It has a molecular 
mass  of  2030.8 Da,  determined  by MALDI‐TOF.  The molecular mass  of  the  unfolded  synthetic 
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2.2. Electrophysiological Screening against Voltage‐Gated and Ligand‐Gated Ion Channels 
The masses  of  the  synthetic  peptides were determined  by MALDI‐TOF,  validating  that  the 
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against a panel of NaV, KV and CaV channels, as well as nAChRs, according to their framework. 
Figure 2. Purification of crude venom of C. asiaticus. (A) RP-HPLC chromatogram of C. asiaticus venom.
The peak indicated in the box was collected for further purification; (B) Ion exchange chromatogram of
the peak fractions collected in the first purification step. The indicated peaks were subjected to another
RP-HPLC purification step; (C) RP-HPLC1 chromatogram as indicated in (B). Edman degradation of
the first peak, Asi14a, revealed the amino acid sequence as described; (D) RP-HPLC2 chromatogram,
as indicated in Figure 2B. Edman degradation of this peak, Asi3a, revealed the amino acid sequence as
described above. The brown lines in (A,C,D) are acetonitrile gradients. The line in (B) shows the ion
exchange gradient.
The last peptide was found in the venom of C. australis and was named AusB. It has a molecular
mass of 2030.8 Da, determined by MALDI-TOF. The molecular mass of the unfolded synthetic peptide
is 2032.2 Da, determined by LC-MS, and correlates with the calculated masses of the oxidized peptide
(2030.2 Da) and for reduced AusB (2032.2 Da). Figure 3 shows the RP-HPLC purification chromatogram.
2.2. Electrophysiological Screening against Voltage-Gated and Ligand-Gated Ion Channels
The masses of the synthetic peptides were determined by MALDI-TOF, validating that the
peptides were folded successfully. Peptides were purified and electrophysiologically screened against
a panel of NaV, KV and CaV channels, as well as nAChRs, according to their framework.
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2.2.1. Lo6/7a and Lo6/7b
Lo6/7a and Lo6/7b have a cysteine framework VI/VII, and both belong to the O or I3- superfamily
according to the conotoxin classification described by Akondi et al. [2]. Therefore, the folded peptides
were screened against a panel of NaV and KV channels (Figure 4). Preliminary screening on CaV
channels did not reveal significant inhibition of the channel (results not shown). Therefore, up to now,
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Figure 4. Electrophysiological screening of Lo6/7a and Lo6/7b. * Represents traces after toxin
application (1 µM) and overlapping control traces before toxin application.
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2.2.2. Asi3a
Asi3a belongs to the M-superfamily from which other members target NaVs, KVs or nAChRs.
Therefore, we performed an electrophysiological screening against a panel of these channels, visualized
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Figure  5. Electrophysiological  screening of Asi3a on NaV  and KV  channels  (10  μM)  and nAChRs   
(5  μM).  *  Represents  traces  after  toxin  application  and  overlapping  control  traces  before  toxin 
application. 
2.2.3. Asi14a 
Asi14a  is another peptide  found  in  the venom  from C. asiaticus. Conopeptides  from  the  J‐ or   
L‐superfamily mainly act on nAChRs and KVs. Therefore, we electrophysiologically screened Asi14a 
against  a  selected  panel  of  these  channels  (Figure  6). No  antagonistic  activity  of Asi14a  could   
be observed. 
Figure 5. Electrophysiological screening of Asi3a on NaV and KV channels (10 µM) and nAChRs (5 µM).
* Represents traces after toxin application and overlapping control traces before toxin application.
2.2.3. Asi14a
Asi14a is another peptide found in the venom from C. asiaticus. Conopeptides from the J- or
L-superfamily mainly act on nAChRs and KVs. Therefore, we electrophysiologically screened Asi14a
against a selected panel of these channels (Figure 6). No antagonistic activity of Asi14a could
be observed.









The  peptide was  electrophysiologically  screened  against  a  panel  of NaVs,  KVs  and  nAChRs  as 
expressed  heterologously  in  Xenopus  laevis  oocytes  (Figure  7).  Up  to  now,  no  target  could   
be identified. 
Figure 6. Electrophysiological screening of Asi14a on KV channels (10 µM) and nAChRs (5 µM).
* Represents traces after toxin application and overlapping control traces before toxin application.
2.2.4. AusB
from C. australis is a disulfide poor peptide, having only one Cys-bond. Since no function
was previously assigned to such conopeptides, its effect on a large panel of channels was evaluated.
The peptide was electrophysiologically screened against a panel of NaVs, KVs and nAChRs as expressed
heterologously in Xenopus laevis oocytes (Figure 7). Up to now, no target could be identified.
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Figure 7. Electrophysiological screening of AusB (10 µM) on a panel of NaV, KV and nAChRs.
* Represents traces after toxin application and overlapping control traces before toxin application.
2.3. Antibacterial Activity
The five new conopeptides were screened against 29 Gram-negative and 10 Gram-positive
bacterial strains and two yeast strains (Table 2). A turbid zone of inhibition was only obtained for
Lo6/7a against the Gram-positive strain Bacillus megaterium ATCC13632. For the other peptides,
no growth inhibition was observed.
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Table 2. List of yeasts, Gram-negative and Gram-positive bacteria used in antimicrobial screening of
five different conopeptides.
Gram-Negative Bacteria Gram-Positive Bacteria
1 Aeromonas hydrophila ATCC7966 1 Bacillus megaterium ATCC13632
2 Agrobacterium tumefaciens A208 2 Bacillus subtilis LMG 7135
3 Azospirillum brasilense Sp7 3 Brevibacterium linens ATCC9172
4 Bordetella avium 197N 4 Corynebacterium glutamicum DSM20300
5 Brevundimonas diminuta LMG 2088 5 Lactobacillus plantarum LMG-P21295
6 Burkholderia cepacia LMG 1222 6 Lactobacillus rhamnosus GG LMG 6400
7 Burkholderia gladioli LMG 2216 7 Mycobacterium smegmatis DSM43756
8 Burkholderia vietnamensis LMG 10927 8 Rhodococcus erythropolis N11
9 Chromobacterium violaceum CV026 9 Staphylococcus aureus ATCC6358
10 Citrobacter freundii ATCC8090 10 Streptomyces lividans TK24
11 Enterobacter aerogenes ATCC13048
12 Erwinia amylovora CFBP1430 Yeast
13 Erwinia carotovora LMG 2458 1 Candida albicans CAI4
14 Proteus vulgaris LMM2011 2 Saccharomyces cerevisiae W303-1A
15 Pseudomonas aeruginosa PA14
16 Pseudomonas entomophila L48
17 Pseudomonas fluorescens Pf0-1
18 Pseudomonas putida KT2440
19 P. syringae pv. tabaci LMG 5192
20 Rhizobium etli CNPAF512
21 Salmonella enteritidis ATCC13076
22 Serratia entomophila DSM12358
23 Shigella flexneri LMG 10472
24 Sphingomonas wittichii RW1
25 Variovorax paradoxus LMG 1797
26 Vibrio harveyi BB120
27 Xanthomonas axonopodis pv. manihotis LMG 784
28 Xanthomonas alfalfae pv. alfalfae LMG 497
29 Yersinia enterocolitica LMG 7899
3. Discussion
In this report, we describe five novel conopeptides, discovered in the venom of C. longurionis,
C. asiaticus and C. australis. These novel sequences have different cysteine frameworks and some of
them likely represent new subgroups, based on sequence comparison with known conotoxins.
3.1. Conopeptide Alignment and Classification
Peptide Lo6/7a is a 24-residue conotoxin isolated from the venom of C. longurionis. Depending on
the target, peptides from the O-superfamily are subdivided into different families: ω-conotoxins act
on CaV channels; κ-conotoxins target KV channels; and µO- or δ-conotoxins influence NaV channels.
By performing a Conoserver alignment search on Lo6/7a, the highest percentage of similarity (92%)
was obtained for Pr6c from Conus parius [8] (Figure 8). Up to now, the target from Pr6c also remains to
be discovered, but the authors suggested the peptide to be either anω- or κ-conotoxin. Despite the
high sequence identity of Lo6/7a with Pr6c, we could not demonstrate such activity on CaV or KV
channels unequivocally. Another peptide from Conus textile (a peptide causing convulsions in mice) has
a similarity percentage of 59% [20]. This peptide induces symptoms characterized by “sudden jumping
activity followed by convulsions, stretching of limbs and jerking behavior”. The authors predicted
that this peptide belongs to a new undefined class of conotoxins. Two other peptides, Vc7.4 and
Vc7.3, from Conus victoriae were described by Robinson et al. (2014) [21]. In this study, the precursor
sequences of Vc7.4 and Vc7.3 were identified, and it was shown that these peptides, as well as the
textile convulsant peptide (C. textile), are members of a previously-undefined conotoxin superfamily,
which was designated U-superfamily. This peptide superfamily shares the cysteine framework (VI/VII)
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of most members of the O1-, O2- and O3-superfamilies. However, the pre- and pro-peptide sequences
substantially differ from other known conotoxin superfamilies. Moreover, when the O-superfamily
is compared with the U-superfamily, there is little similarity in the intercysteine loop composition or
length (i.e., the U-superfamily has only two residues, while the O-superfamily conotoxins have six) [21].
The specific physiological target of these peptides has not yet been derived. However, given the
similarity in the mature peptide sequence of these conotoxins with Lo6/7a, it is likely that they belong
to the same superfamily and share a similar target.
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Asi3a  is  classified  in  the  M‐superfamily,  acting  generally  on  NaVs  (μ‐conotoxins),  KVs   
(κM‐conotoxins) and nAChRs (ψ‐conotoxins). Asi3a shows most identity with conotoxin Pr3a from 
Conus  parius  (87%)  (Figure  10).  Jimenez  et  al.  [22]  classified  this  peptide  as  an M‐superfamily 
conotoxin and performed a bioassay  that was carried out by  intraperitoneal  injection of  fish. The 
purified  peptide  Pr3a  (1  nmol)  resulted  in  paralysis  of  the  fish  after  ~5  min.  A  functional 
characterization of peptides similar to Asi3a has not yet been performed. 
Figure 8. Alignment of Lo6/7a with conotoxins, sorted by the percentage of identity (indicated in
the left column). References: Pr6c (C. parius, [22]), Vc7.4 (C. victoriae, [21]), a convulsant peptide fro
C. textile [20,23], Tx6.5 (C. textile, [24]), Vc7.3 (C. victoriae, [21]) and Cl6a (C. californicus, [25]).
Peptide Lo6/7b aligns with members of the O-superfamily, although with low percentages of
similarity (Figure 9). LtVIC is the only peptide from which a physiological target has been identified
up to now. This conotoxin inhibits sodium currents in adult rat dorsal root ganglion neurons [26].
Therefore, LtVIC is considered a µ(O)-conotoxin. In our electrophysiological set-up, we could not
identify Lo6/7b as a µ(O)-conotoxin. Nevertheless, the similarity of Lo6/7a with LtVIC (46%) is
rather low.
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Figure 9. Alignment of Lo6/7b with conotoxins, sorted by percentage of identify (indicated in
the left column). References: E6.2 (C. ermineus, unknown ref.); LtVIC (C. litteratus, [26]); Vc6.28
(C. victoriae, [21]); M1 (C. militaris, [27]); Conotoxin-3 (C. striatus, [28]); Bu9 (C. bullatus, [29]); 6.5
( . pulicarius, [30]); 6.6 ( . pulicarius, [30]).
Asi3a is classified in the M-superfamily, acting generally on NaVs (µ-conotoxins),
KVs (κM-conotoxins) and nAChRs (ψ-conotoxins). Asi3a shows most identity with conotoxin Pr3a fro
Conus parius (87%) (Figure 10). Jimenez et al. [22] classified this peptide as an M-superfamily conotoxin
and performed a bioassay that was carried out by intraperitoneal injection of fish. The purified peptide
Pr3a (1 nmol) resulted in paralysis of the fish after ~5 min. A functional characterization of peptides
similar to Asi3a has not yet been performed.
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Figure 10. lign ent of si3a ith conotoxins, sorted by percentage of identity (indicated in the left
colu n). eferences: Pr3a ( . parius, [22]), r S -01 ( . arenatus, [31]); Pu3.7 ( . pulicarius, [30]);
Pu3.3 ( . pulicarius, [24]); Pu3.4 ( . pulicarius, [32]); Bet Ib ( . betulinus, [33]); s S -021
( . tessulatus, [31]).
Asi14a belongs to the A-, L- or J- superfamilies acting typically on nAChRs (L- and A-superfamily).
The J-superfamily characteristically targets KV channels. No meaningful alignment with other A-, L- or
J-superfamily peptides could be performed. Therefore, we conclude that Asi14a probably belongs to
a new subclass of framework XIV proteins. A BLAST homology search with Asi14a did not reveal
similarity to any known peptide or protein.
AusB is an unusual peptide found in the venom of C. australis. Containing 18 amino acids,
AusB has only one cysteine bond classifying it among the disulfide poor conopeptides. A Conoserver
search resulted in a poor quality alignment, and a BLAST did not align the peptide with other relevant
peptides either. Since AusB could not be atched with any disulfide-poor conotoxin, this peptide
represents a new family, which we will label ConoGAY peptides, named after the first three N-terminal
amino acids of this peptide.
.2. t i ti ss s i t e est of I e tifyi g ovel har acological Targets
it r t i i ti f c t i t ti l ti i i
i s et al. [34], Ji Biggs et al. (2 07) discovered conolysin-Mt,
a disulfide-p or conopeptide that was initia ly tested on c t t ti l
c l apse within seconds. The pe tide was al o evaluated for antago ism against three bact rial strains:
E. coli D21, E. coli ATCC 25922 and S. aureus ATCC 6538. The authors no iced low antibacterial ctivity
aga nst the two E. coli strains te ed, with a min mal inhibitory concentration (MIC) > 50 µM. The MIC
against the Gram-positive S. aureus was 25–50 µM [34]. Jiang et al. (2011) tested a cy ine-rich peptide
library m micking µ-conotoxins fr m Conus geographus on antiviral activity g inst influenza virus [35].
Finally, Takad et al. (2006) showed that ast ropine A, a sialidase-inh biting conotoxin-like peptide
from th marine sponge Asteropus simplex, might be an i portant lead compou d for antibacterial and
a tiviral drug development [36]. This is inter sting since multidrug res stant bacteria nfection are a
growing global health problem. Antimicrobial pe tides from poison us animals are described for a
number of scorpion peptides, as well as peptides from snakes, frogs, bees (Apis sp.), etc., as part of
their host defense system [37–46]. For scorpion in particular, it has been proposed that the presence
of antibacterial peptides protects the venom gland from pathogenic infections or potentiates toxin
action [47]. Scorpion antimicrobial peptides (AMP) re positively-charged amphip thic peptides
divided into three structural categories: (1) cysteine containing peptides with mainly three or
four isulfide bridges; (2) peptides with an amphipathic α-h lix, but lacking cysteine r sidues;
and (3) peptides rich in Pro and Gly amino acids. One example of a cystei containing s orpion
AMP is scorpine, which showed activity against both Gram-positive (B. subtilis) and Gram-nega ive
(K. pneumonia) bact ria (MIC 1–10 µM) [47]. When it comes to conotoxins, this path of investigation
remains underexpl red.
I this work, all peptides were l ctrophysiol gically tested on relevant ion channels predicted by
their cysteine arrangement. These result indicate novel functionalities other than exp cted based on
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their cysteine framework, since no activity could be identified on all of the targets studied. In order to
further determine the mode of action and the potential molecular targets of these conotoxins, in vivo
or ex vivo assays should be performed. As such, symptoms observed after intracranial injection of
toxins in mice may provide indications on the type of receptor or channel targeted. Furthermore
experiments on neuromuscular preparations may possibly identify a pre- or post-synaptic effect or
even sodium/potassium or nicotinic antagonism. In addition, a broad screening was performed
against a collection of micro-organisms. Low and very specific activity was observed for Lo6/7a
against Bacillus megaterium ATCC13632. Since 1 mM is a very high test concentration and the halo was
small, the inhibitory effect of Lo6/7a cannot be attributed as the main action of this peptide. Examples
of scorpion antimicrobial peptides that potently target B. megaterium are meucin-13 (MIC 0.25 µM),
meucin-18 (MIC 0.25 µM) and pantinin-3 (MIC 6 µM) [47].
4. Materials and Methods
4.1. Cone Snail Specimens and Venom Extraction
Specimens of C. longurionis, C. asiaticus and C. australis (identified by Kiener (1845), da Motta
(1985) and Holten (1802), respectively, and classified by Tucker and Tenorio [48]) were collected from
the Indian Ocean near Tamil Nadu, India. The venomous apparatuses (venom bulbs and venom ducts)
were extracted from the specimens as described previously [49]. The collected tissues were preserved
in RNAlater solution (Ambion, Austin, TX, USA) and stored at −20 ◦C. The venomous apparatuses
were used for peptide/protein extraction.
4.2. Peptide Fractionation and Purification
Two steps were followed for the separation of the venom compounds of C. longurionis. In the first
step, the lyophilized crude venom powder was solubilized into 50% acetonitrile (ACN)/water and
aliquots were loaded on a Gel filtration Superdex™ Peptide 10/300 GL column with 50% ACN/water
as the mobile phase (flow rate 0.5 mL/min) to separate the peptides and proteins based on their
size. Two sample collections obtained were stored overnight at −80 ◦C, freeze-dried and finally
solubilized in 5% ACN/water. For the second step, an analytical Vydac C18 column (218MS54,
4.6 mm × 250 mm, 5-µm particle size; Grace, Deerfield, IL, USA) with a two solvent system was
used: (A) 0.1% trifluoroacetic acid (TFA)/H2O and (B) 0.085% TFA/ACN. The sample was eluted
at a constant flow rate of 1 mL/min with a 0%–80% gradient of Solvent B over 90 min (1% can per
minute after 10 min of Solvent A). The HPLC column elutes were monitored by a UV/VIS-155 detector
(214 nm and 280 nm; Gilson, Middleton, WI, USA).
Three steps were followed for the separation of the venom compounds of C. asiaticus. In the first
step, the lyophilized crude venom powder was solubilized using 5% acetonitrile (ACN)/water and
aliquots were loaded on an analytical Vydac C18 column (218MS54, 4.6 mm × 250 mm, 5-µm particle
size; Grace, Deerfield, IL, USA) with a two-solvent system: (A) 0.1% trifluoroacetic acid (TFA)/H2O
and (B) 0.085% TFA/ACN. The sample was eluted at a constant flow rate of 1 mL/min with a 0%–80%
gradient of Solvent B over 90 min (1% ACN per minute after 10 min of Solvent A). The HPLC column
elutes were monitored by a UV/VIS-155 detector (214 nm and 280 nm; Gilson, Middleton, WI, USA).
The largest peak was collected and freeze-dried for further purification. This fraction collection was
subjected to a second purification step, namely ion exchange chromatography, using a Luna SCX
column (Phenomenex, Torrance, CA, USA, 4.6 mm × 250 mm, 5-µm particle size) at room temperature.
The solutions used for ion exchange chromatography were: (A) 20 mM KH2PO4, pH 2.5: ACN (75:25)
and (B) 20 mM KH2PO4/0.5 M KCl:ACN (75:25). The sample was eluted using a three-step protocol:
0% Solution B for 15 min, 0%–100% Solution B for 30 min and 100% B for 15 min at a flow rate
of 1 mL/min. The collected fractions were stored overnight at −80 ◦C and freeze-dried. A third
purification step was performed by RP-HPLC, using the same conditions as described for the first
purification step.
Mar. Drugs 2016, 14, 199 13 of 18
Two steps were followed for the separation of the venom compounds of C. australis. In the first step,
the lyophilized crude venom powder was solubilized into 50% acetonitrile (ACN)/water, and aliquots
were loaded on a Gel filtration Superdex™ Peptide 10/300 GL column with 50% ACN/water as
the mobile phase (flow rate 0.5 mL/min) to separate the peptides and proteins based on their size.
Three sample collections were made that were stored overnight at −80 ◦C, freeze-dried and finally
solubilized in 5% ACN/water. For the second step, an analytical Vydac C18 column (218MS54,
4.6 mm × 250 mm, 5-µm particle size; Grace, Deerfield, IL, USA) with a two-solvent system was
used: (A) 0.1% trifluoroacetic acid (TFA)/H2O and (B) 0.085% TFA/ACN. The sample was eluted at
a constant flow rate of 1 mL/min with a 0%–80% gradient of Solvent B over 90 min (1% ACN per
minute after 10 min of Solvent A). The HPLC column elutes were monitored by a UV/VIS-155 detector
(Gilson, Middleton, WI, USA) scanning both 214 nm and 280 nm.
4.3. Peptide Sequencing
Isolated Lo6/7a, Lo6/7b, Asi3a, Asi14a and AusB were collected and freeze-dried for direct
peptide sequencing and molecular mass analysis (MALDI-TOF; 4800 Analyzer, Applied Biosystems,
Foster City, CA, USA). A Protein Sequencer PPSQ-31A/33A (Shimadzu, Kyoto, Japan) was used
to determine the amino acid sequence of the separated compounds. Samples were loaded onto a
polybrene-pretreated, precycled glass fiber disk and Edman sequenced for 30 residue cycles.
Theoretically-calculated masses of the peptides were done with an online Peptide Mass Calculator
(Peptide Protein Research Ltd., Hampshire, UK). Peptide homology search was generated online at
Conoserver.org [50,51] and NCBI (Rockville Pike, Bethesda MD, USA) [52]. The CLC Main Workbench
7 software was used to align the peptide sequences (CLC bio, QIAGEN, Hilden, Germany).
4.4. Peptide Synthesis and Folding
Lo6/7a and Lo6/7b were synthesized by GeneCust (Elange, Luxemburg). Asi3a, Asi14a and
AusB were synthesized by GenicBio Limited (Shanghai, China). All peptides, except AusB, were
C-terminally amidated, purified by HPLC and analyzed with LC-MS, then freeze-dried and stored
at −20 ◦C until use. The peptides were folded using an oxidative folding solution (1 mM reduced
glutathione (Sigma, Munich, Germany), 1 mM oxidized glutathione (Roche, Mannheim, Germany),
1 mM ethylenediaminetetraacetic acid (EDTA; Sigma, Munich, Germany) and 100 mM Tris/HCl
(Merck, Darmstadt, Germany) [53]). The solution was adjusted to pH 7.63 with 10 M NaOH (Merck,
Darmstadt, Germany). Prior to functional characterization, the purity and folding of the synthetic
peptides was validated (MALDI-TOF MS), and a chromatographic characterization was undertaken by
RP-HPLC. On the basis thereof, a careful comparison of the retention time with the one of the native
material was done.
4.5. Preparation of RNA for Functional Testing in Xenopus Oocytes
The RNA preparation of the different NaV, KV channels and nAChRs was done as follows:
Complementary DNA (cDNA) encoding the NaV channels was subcloned into the corresponding
vector: the α-subunits rNaV1.1/pLCT1 (NotI), rNaV1.2/pLCT1 (NotI), rNaV1.3/pNa3T (NotI),
rNaV1.4/pUI-2 (NotI), hNaV1.5/pcDNA3.1 (XbaI), mNaV1.6/pLCT (NotI), rNaV1.7/pBSTA.rPN1
(SacII), hNaV1.8/hPN3-pBSTAcIIR (NotI) and the corresponding β-subunits rβ1/pSP64T (EcoRI) and
hβ1/pGEM-HE (NheI).
For KV channels, channel-encoding cDNA was subcloned into the corresponding vector:
rKV1.1/pGEM-HE (EcoRI), rKV1.2/pGEM-HE (SphI), hKV1.3/pGEM-HE (NotI), rKV1.4/pGEM-HE
(NotI), rKV1.5/pGEM-HE (SalI), rKV1.6/pGEM-HE (NdeI), hKV3.1/pGEM-HE (XbaI), hKV10.1/pSGem
(SfiI), hERG/pSp64 (EcoRI).
Complementary DNA encoding the nAChR-channels was subcloned into the corresponding
vector: hα3/pcDNA3 (XbaI), hα4/pGEM-HE (NheI), cα7/pBlueScript (NotI), hβ2/pSP64 (PvuII),
hβ4/pcDNA3 (XbaI), rα1/pSP0oD (SalI), rβ1/pSP0oD (SalI), rδ/pSP0oD (SalI), rε/pSP0oD (SalI).
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4.6. Electrophysiological Recordings
The harvesting of Stages V–VI oocytes from anaesthetized female Xenopus laevis frogs was
described previously [54]. Using a nanoinjector (Drummond, Broomall, PA, USA), the selected
oocytes (Stages V–VI) were injected with 40–70 nL mRNA (100–2000 ng/L) and 4–20 nL mRNA for
KV channels. Then, the oocytes were stored at 16 ◦C in a geomycin (1.25 mL/L; Rotexmedica, Trittau,
Germany) and theophylline (80 mg/L; ABC chemicals, Wauthier Braine, Belgium) supplemented
ND96 solution, except for KV channels, where theophylline was not added.
Whole-cell currents from oocytes were recorded at room temperature (18–22 ◦C) by the
two-electrode voltage clamp technique using a GeneClamp 500 amplifier (Axon Instruments,
Foster City, CA, USA) controlled by a pClamp data acquisition system (Molecular Devices, Sunnyvale,
CA, USA). Oocytes were placed in a bath containing ND96 solution. Voltage and current electrodes
were filled with 3 M KCl, and the resistances of both electrodes were maintained as low as possible
(0.5 to 1.5 MΩ). To eliminate the effect of the voltage drop across the bath grounding electrode, the bath
potential was actively controlled by a two-electrode bath clamp. Leak subtraction was performed
using a −P/4 protocol.
For NaV channels, whole-cell current traces were evoked every 5 s by a 100-ms depolarization to
the voltage corresponding to the maximal activation of the NaV-subtype in control conditions (0 mV),
starting from a holding potential of −90 mV. The elicited currents were sampled at 20 kHz and filtered
at 2 kHz using a four-pole, low-pass Bessel filter. Concentration-response curves were constructed by
adding different toxin concentrations directly to the bath solution.
KV1.1–KV1.6 and KV3.1 currents were evoked by 500-ms depolarizations to 0 mV followed by a
500-ms pulse to −50 mV, from a holding potential of −90 mV. The elicited currents were sampled at
2 kHz and filtered at 500 Hz using a four-pole low-pass Bessel filter. KV10.1 currents were evoked by
2-s depolarizing pulses to 0 mV from a holding potential of −90 mV. hERG or KV11.1 peak and tail
currents were generated by a 2.5-s prepulse from−90 mV–40 mV followed by a 2.5-s pulse to−120 mV.
KV10.1 currents were sampled at 2 kHz and filtered at 1 kHz; hERG currents were sampled at 10 kHz
and filtered at 1 kHz using a four-pole low-pass Bessel filter.
For measuring nAChR currents, the following conditions were applied: during recordings, oocytes
were continuously perfused with ND96 at a rate of 2 mL/min, with the conopeptides applied during
30 s before ACh was added. ACh (200 µM) was applied for 2 s at 2 mL/min, with 30-s washout periods
between different ACh applications and 200 s after toxin application. The percentage response or
percentage inhibition was obtained by averaging the peak amplitude of at least three control responses
(two directly before exposure to the peptide and one after 200 s washout). Whole-cell current traces
were evoked from a holding potential of −90 mV.
Data were analyzed using pClamp Clampfit 10.0 (Molecular Devices, Sunnyvale, CA, USA)
and Origin 7.5 software (Originlab, Northampton, MA, USA) and presented as the result of at least
3 independent experiments (n ≥ 3).
4.7. Growth Media and Micro-Organisms
Growth media were prepared as follows (1 L deionized water):
LB (lysogeny broth): 0.5% yeast extract (BD Biosciences, San Jose, CA, USA); 1% bacterial peptone
(International Medical); 1% NaCl (Fisher Scientific, Aalst, Belgium); MRS (Man Rogosa and Sharpe):
55 g Difco™ lactobacilli MRS broth (BD Biosciences, San Jose, CA, USA); NB (nutrient broth): 8 g
nutrient broth (Oxoid); TSB (trypticase soy broth): 3%, BD Biosciences; TY (tryptone yeast extract): 3 g
yeast extract, 5 g tryptone (International Medical); 7 mM CaCl2 (VWR International, Leuven, Belgium);
YEP (yeast extract peptone): 10 g yeast extract, 10 g bacterial Bacto peptone; YPD (yeast extract peptone
dextrose): 10 g yeast extract, 20 g bacterial peptone, 20 g dextrose. Media were solidified with agar
(1.5%) For this study, 29 Gram-negative and 10 Gram-positive strains were used, together with 2 yeast
strains. Strain names, growth conditions and sources are summarized in the Supplementary Table S1.
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4.8. Antibacterial Assays
The different bacterial and yeast strains were inoculated in 5 mL of the appropriate medium and
incubated overnight at the appropriate temperatures and shaking at 200 rpm. Next, agar plates were
overlaid with 5 mL soft agar (0.5%), seeded with 50 µL of the overnight cultures (~109 CFU/mL).
Cell lawns were supplemented with 5-µL spots of the different conotoxins and derivatives
(concentration ~1 mM) and air-dried. Plates were incubated overnight and evaluated for the presence
of zones of growth inhibition or halos. ND96 buffer was used as the negative control.
5. Conclusions
We purified five novel conotoxins from the venom glands of three Indian cone snail species that
were largely unexplored up to now. The discovered sequences open new perspectives concerning
the conopeptide classification and hint to new representatives of new classification groups since the
amino acid sequences significantly differ from what is known in the literature. No targets could be
attributed to the peptides, pointing to novel functionalities. Further experiments on other ion channels
or receptors are required to reveal the physiological impact of these conopeptides.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/14/11/199/s1,
Table S1: Strain names, growth conditions (media and growth temperature) and source of the bacterial strains
used in this work.
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